AstraZeneca Medications
WEBAstraZeneca medications. The list below contains full Prescribing Information for all of our medicines and a range of websites dedicated to providing you with product-specific information. The information contained below is intended for US residents only.
Airsupra (PT027) approved in the US for asthma - AstraZeneca
WEBJan 11, 2023 · Airsupra is a first-in-class, pressurised metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US. It is being developed by AstraZeneca and Avillion.
Respiratory and Immunology - Our therapy areas - AstraZeneca
WEBWe are focused on chronic respiratory diseases including asthma and chronic obstructive pulmonary disease (COPD), as well as immune-driven diseases such as lupus. We follow the science to address tough and complex, unsolved problems - targeting the underlying biology and developing effective new drug modalities and combinations with the ...
AIRSUPRA® (albuterol/budesonide) now available as the ... - AstraZeneca US
WEBJan 22, 2024 · Adults living with asthma now have an approved rescue treatment designed to treat both symptoms and inflammation to help prevent asthma attacks. AstraZeneca announces AIRSUPRA ® (albuterol/budesonide), is now commercially available in …
Tezspire (tezepelumab) approved in the US for severe asthma - AstraZeneca
WEBDec 17, 2021 · AstraZeneca and Amgen’s Tezspire (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and paediatric patients aged 12 years and older with severe asthma. 1
TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma
WEBDec 17, 2021 · TEZSPIRE™ (tezepelumab) is being developed by AstraZeneca in collaboration with Amgen as a potential first-in-class human monoclonal antibody that inhibits the action of TSLP, a key epithelial ...
FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA
WEBDec 17, 2021 · Tezspire is a first-in-class biologic for severe asthma that acts at the top of the inflammatory cascade by targeting thymic stromal lymphopoietin (TSLP), an epithelial cytokine. 3 It is the first and only biologic to consistently and significantly reduce asthma exacerbations across Phase 2 and 3 clinical trials, which included a broad ...
Avillion announces US approval of AstraZeneca's Airsupra (PT027) …
WEBJan 11, 2023 · Airsupra is the first and only rescue medication approved in the US for as-needed use to reduce risk of asthma exacerbations. Approval based on successful Phase III trial programme conducted by...
AIRSUPRA (PT027) approved in the US for asthma - Asthma and …
WEBAIRSUPRA is a first-in-class, pressurized metered-dose inhaler (pMDI), fixed-dose combination rescue medication containing albuterol, a short-acting beta2-agonist (SABA), and budesonide, an anti-inflammatory inhaled corticosteroid (ICS) in the US. It is being developed by AstraZeneca and Avillion.
Avillion, AstraZeneca asthma rescue treatment given FDA approval
WEB4 days ago · Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA).
Skip to content